Late diagnosis defines a unique population of long-term survivors of cystic fibrosis

被引:128
作者
Rodman, DM
Polis, JM
Heltshe, SL
Sontag, MK
Chacon, C
Rodman, RV
Brayshaw, SJ
Huitt, GA
Iseman, MD
Saavedra, MT
Taussig, LM
Wagener, JS
Accurso, FJ
Nick, JA
机构
[1] Univ Colorado, Hlth Sci Ctr, Cyst Fibrosis Ctr, Denver, CO 80262 USA
[2] Natl Jewish Med & Res Ctr, Denver, CO USA
[3] Childrens Hosp, Denver, CO 80218 USA
关键词
genotype; lung; mutation; Pseudomonas aeruginosa; non-tuberculous mycobacteria; sweat chloride;
D O I
10.1164/rccm.200403-404OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although the median survival for patients with cystic fibrosis (CF) is 32.9 years, a small group of patients live much longer. We analyzed the genotype and phenotype of CF patients 40 years and older seen between 1992 and 2004 at the National Jewish Medical and Research Center (n = 55). These patients were divided into two groups according to age at diagnosis: an early diagnosis (ED) group, median age at diagnosis 2.0 years (range 0.1-15 years, n = 28), and a late diagnosis (LD) group, median age of diagnosis 48.8 years (range 24-72.8 years, n = 27). Consistent with the hypothesis that the CFTR genotype affects the age at diagnosis, CFTR Delta F508 homozygous individuals were more common in the ED group. Although patients in the ED group were predominantly male, the majority of LD patients were female. Patients with CF diagnosed late had a significantly lower prevalence of pancreatic insufficiency and CF-related diabetes, and better lung function. Fewer patients in the LD groups were infected with Pseudomonas aeruginosa, whereas a greater percentage had cultures positive for nontuberculous mycobacteria. This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ distinctly from survivors of long-term CF diagnosed as children.
引用
收藏
页码:621 / 626
页数:6
相关论文
共 42 条
[1]   NONTUBERCULOUS MYCOBACTERIAL DISEASE IN ADULT CYSTIC-FIBROSIS PATIENTS [J].
AITKEN, ML ;
BURKE, W ;
MCDONALD, G ;
WALLIS, C ;
RAMSEY, B ;
NOLAN, C .
CHEST, 1993, 103 (04) :1096-1099
[2]   VARIABILITY IN CYSTIC-FIBROSIS [J].
BONFORTE, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (17) :1855-1855
[3]   Nonclassic cystic fibrosis and CFTR-related diseases [J].
Boyle, MP .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :498-503
[4]   VARIABLE SEVERITY OF PULMONARY-DISEASE IN ADULTS WITH IDENTICAL CYSTIC-FIBROSIS MUTATIONS [J].
BURKE, W ;
AITKEN, ML ;
CHEN, SH ;
SCOTT, CR .
CHEST, 1992, 102 (02) :506-509
[5]  
Choo-Kang L R, 2000, Curr Opin Pulm Med, V6, P521, DOI 10.1097/00063198-200011000-00011
[6]   Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis [J].
Corey, M ;
Edwards, L ;
Levison, H ;
Knowles, M .
JOURNAL OF PEDIATRICS, 1997, 131 (06) :809-814
[7]  
Cystic Fibrosis Foundation, 2004, PAT REG 2003 ANN DAT
[8]  
DEMKO CA, 1994, J CLIN EPIDEMIOL, V43, P125
[9]   Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis [J].
Durno, C ;
Corey, M ;
Zielenski, J ;
Tullis, E ;
Tsui, LC ;
Durie, P .
GASTROENTEROLOGY, 2002, 123 (06) :1857-1864
[10]   Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis [J].
Emerson, J ;
Rosenfeld, M ;
McNamara, S ;
Ramsey, B ;
Gibson, RL .
PEDIATRIC PULMONOLOGY, 2002, 34 (02) :91-100